BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Price & Overview
NASDAQ:BVXV • US09073Q2049
Current stock price
The current stock price of BVXV is 1.36 USD. Today BVXV is up by 3.82%. In the past month the price increased by 2.26%. In the past year, price decreased by -87.02%.
BVXV Key Statistics
- Market Cap
- 4.967M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.86
- Dividend Yield
- N/A
BVXV Stock Performance
BVXV Stock Chart
BVXV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BVXV. When comparing the yearly performance of all stocks, BVXV is a bad performer in the overall market: 91.2% of all stocks are doing better.
BVXV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BVXV. Both the profitability and financial health of BVXV have multiple concerns.
BVXV Earnings
BVXV Forecast & Estimates
7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
BVXV Groups
Sector & Classification
BVXV Financial Highlights
Over the last trailing twelve months BVXV reported a non-GAAP Earnings per Share(EPS) of -6.86. The EPS decreased by -93.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BVXV Ownership
BVXV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BVXV
Company Profile
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.
Company Info
IPO: 2007-06-07
BIONDVAX PHARMACEUTICALS-ADR
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM 74036 IL
CEO: Amir Reichman
Employees: 33
Phone: 97289302529.0
BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ
What does BIONDVAX PHARMACEUTICALS-ADR do?
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.
What is the current price of BVXV stock?
The current stock price of BVXV is 1.36 USD. The price increased by 3.82% in the last trading session.
Does BIONDVAX PHARMACEUTICALS-ADR pay dividends?
BVXV does not pay a dividend.
What is the ChartMill rating of BIONDVAX PHARMACEUTICALS-ADR stock?
BVXV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for BVXV stock?
7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
How many employees does BIONDVAX PHARMACEUTICALS-ADR have?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) currently has 33 employees.
Can you provide the market cap for BIONDVAX PHARMACEUTICALS-ADR?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a market capitalization of 4.97M USD. This makes BVXV a Nano Cap stock.